Polatuzumab vedotin-piiq - Biologic Drug Details

Summary for polatuzumab vedotin-piiq

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for polatuzumab vedotin-piiq Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for polatuzumab vedotin-piiq Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for polatuzumab vedotin-piiq Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Polatuzumab Vedotin-piiq

Last updated: April 3, 2026

What is Polatuzumab Vedotin-piiq?

Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate (ADC). It targets B-cell non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). It combines an anti-CD79b monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE). It was developed by Roche and licensed to Genentech.

Current Market Status

• Approved by the U.S. Food and Drug Administration (FDA) in June 2022 for relapsed/refractory DLBCL in combination with bendamustine and rituximab.
• Approved in the European Union (EU) in November 2022.
• Marketed under the brand name Polivy.

Market Size and Growth Potential

Global lymphoma market value

• The global non-Hodgkin lymphoma (NHL) market was valued at approximately $4.3 billion in 2022.
• Expected Compound Annual Growth Rate (CAGR): 8% from 2023 to 2030.
• DLBCL accounts for 30-40% of NHL cases.

Polatuzumab vedotin-piiq's market share

• Positioned as a second-line therapy for R/R DLBCL.
• Competitors include CAR-T therapies (e.g., axi-cel, tisa-cel), polatuzumab-based regimens, and other ADCs.
• Estimated to capture 10-15% of the R/R DLBCL market by 2025.

Key drivers

• High unmet need in relapsed/refractory settings.
• Favorable efficacy profile with overall response rates (ORR) approximately 50% in clinical trials.
• Regulatory approvals facilitate market penetration.

Revenue Trajectory and Forecasts

Year	Projected Revenue (USD billions)	Assumptions
2023	0.15	Launch phase, early adoption
2024	0.35	Increased adoption, broader approval
2025	0.50	Expansion into earlier lines, growing share
2026	0.70	Market penetration deepens
2027+	0.80+	Maturation, competition factors

Key factors influencing revenue

• Price point estimated at $10,000 per treatment cycle.
• Multiple cycles per patient.
• Approximately 5,000 patients in the U.S. and EU combined eligible annually.
• Market expansion into Asia and other regions could augment revenues.

Competitive Landscape

Major competitors

• CAR-T therapies: Axicabtagene ciloleucel, Tisagenlecleucel.
• Other ADCs: Loncastuximab tesirine.
• Chemotherapy regimens: CHOP, rituximab combinations.

Differentiators

• Faster administration compared to CAR-T.
• Fewer logistical hurdles, less B-cell aplasia.
• Lower manufacturing complexity than some CAR-Ts.

Regulatory and Patent Outlook

• Patent filings in the U.S. extend to 2030.
• Regulatory agencies have approved polatuzumab in combination with other agents for specific indications.
• Competition from biosimilars unlikely before mid-2030s.

Financial Risks and Opportunities

Risks

• Competition from emerging bi-specific antibodies.
• Potential safety concerns impacting approval or market acceptance.
• Manufacturing complexities amid global supply chain issues.

Opportunities

• Growing adoption within combination regimens.
• Expansion into earlier lines of therapy.
• Licensing deals and collaborations in emerging markets.

Summary

Polatuzumab vedotin-piiq is positioned as a significant driver in the R/R DLBCL segment, with moderate to high growth prospects over the next five years. It benefits from regulatory approvals, a high unmet need, and differentiation via its ADC mechanism. Revenue growth depends on expanding indications, timely market access, and competitive dynamics.

Key Takeaways

• Polatuzumab vedotin-piiq's global market profit should reach approximately $0.8 billion annually by 2027.
• It has early approval in the U.S. and EU, with Asia presenting future growth opportunities.
• Competition from CAR-T therapies remains a challenge but ADCs fill a niche for rapid, outpatient treatment.
• Revenue is sensitive to approval timing, pricing strategies, and competitive innovations.

FAQs

Q1: What are the main clinical advantages of polatuzumab vedotin-piiq?
A1: It offers a targeted approach with a manageable safety profile, shorter administration time compared to CAR-T, and efficacy in relapsed/refractory DLBCL.

Q2: How does polatuzumab vedotin-piiq compare price-wise to other treatments?
A2: The approximate price per treatment cycle is set at $10,000, positioning it competitively against CAR-T therapies, which can cost over $370,000 per treatment.

Q3: What is the potential geographic expansion for polatuzumab vedotin?
A3: Expansion into Asian markets, especially China and Japan, is anticipated, contingent on regulatory approvals and pricing negotiations.

Q4: What limitations exist for polatuzumab vedotin's market growth?
A4: Competition from emerging immunotherapies, biosimilars, and potential safety concerns could restrict market penetration.

Q5: What are the main factors influencing polatuzumab vedotin’s patent lifespan?
A5: Patents are granted until 2030 in the U.S., with extensions possible; patent expirations could allow biosimilar entry thereafter.

---

References

[1] Global Data. (2022). Non-Hodgkin lymphoma market analysis.
[2] FDA. (2022). Polatuzumab vedotin-piiq approval announcement.
[3] EvaluatePharma. (2023). Oncology drug market forecasts.
[4] European Medicines Agency. (2022). Polatuzumab marketing authorization details.